...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Thoughts on ZCC

I agree there should be more communication.  But he may be reluctant to give an update if he just doesn't know many of the answers.  Most likely the COVID trial delays are due to factors outside his control. Perhaps he thinks it's better to stay quiet than update and risk getting it wrong.  I'm more accepting of the current situation than most folks. Perhaps that's because I didn't own shares and wasn't riding it down. Given what it is now, I look at how I can best respond to it.

For Zenith, I hope at least we get an update at the AGM as to where we're going.  Are we going to just coast along like this for the next 5 years?

Share
New Message
Please login to post a reply